

Under the Paperwork Reduction Act of 1995, no persons are required to furnish information to the public under penalty of perjury if the information is not requested by a sworn law enforcement officer.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/591,442
Filing Date	September 01, 2006
First Named Inventor	Dena LESHKOWITZ
Art Unit	1653
Examiner Name	Not Yet Assigned
Attorney Docket Number	32488

Sheet	1	of	4
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Cynthia Wilder/	Date Considered	04/10/2008
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents at www.uspto.gov of the 19th century, the Emperor's name precedes the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/591,442		
		Filing Date	September 01, 2006		
		First Named Inventor	Dena LESHKOWITZ		
		Group Art Unit	1653		
		Examiner Name	Not Yet Assigned		
Sheet		Of	4	Attorney Docket Number	32488
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/CW/	8	Cowie et al. "Identification of APC Gene Mutations in Colorectal Cancer Using Universal Microarray-Based Combinatorial Sequencing-by-Hybridization", Human Mutation, 24: 261-271, 2004.			
	9	De Saizieu et al. "Bacterial Transcript Imaging by Hybridization of Total RNA to Oligonucleotide Arrays", Nature Biotechnology, 16: 45-48, 1998.			
	10	Demoulin et al. "The Same TCR (N)DBeta(N)JBeta Junctional Region is Associated with Several Different VBeta13 Subtypes in a Multiple Sclerosis Patient at the Onset of the Disease", Neurobiology of Diseases, 14:470-482, 2003.			
	11	Drmanac et al. "Sequencing by Hybridization (SBH): Advantages, Achievements and Opportunities", Biotechnology, 77: 76-101, 2002.			
	12	Ferrando et al. "Gene Expression Profiling: Will it complement or Replace Immunophenotyping?", Best Practice & Research Clinical Hematology, 16(4): 645-652, 2003.			
	13	Fraser et al. "The VH Gene Repertoire of Splenic B Cells and Somatic Hypermutation in Systemic Lupus Erythematosus", Arthritis Research & Therapy, 5(2): 114-121, 2003.			
	14	Frieze et al. "Optimal Reconstruction of a Sequence from its Probes", Journal of Computational Biology, 6(3/4): 361-368, 1999.			
	15	Gasparotto et al. "Hepatitis C Virus, B-Cell Proliferation and Lymphomas", Leukemia & Lymphoma, 43(4): 747-751, 2002. Abstract.			
	16	Gerry et al. "Universal DNA Microarray Method for Multiplex Detection of Low Abundance Point Mutations", J. Mol. Biol., 292: 251-262, 1999.			
	17	Hodges et al. "Diagnostic Role of Tests for T Cell Receptor (TCR) Genes", J Clin Pathol, 56: 1-11, 2003.			
	18	Kienle et al. "VH Mutation Status and VDJ Rearrangement Structure in Mantle Cell Lymphoma: Correlation With Genomic Aberrations, Clinical Characteristics, and Outcome", Blood, 102(8):3003-3009, 2003.			
	19	Kienle et al. "Distinct Gene Expression Patterns in Chronic Lymphocytic Leukemia Defined by Usage of Specific VH Genes", Blood, 107(5):2090-2093, 2006.			
	20	Kotlan et al. "Immunoglobulin Repertoire of B Lymphocyte Infiltrating Breast Medullary Carcinoma", Human Antibodies, 12(4): 113-121, 2003. Abstract.			
	21	Link et al. "Clues to Etiology of Autoimmune Diseases Through Analysis of Immunoglobulin Genes", Arthritis research, 4:80-83, 2002.			
	22	Messmer et al. "The Pattern and Distribution of Immunoglobulin VH Gene Mutations in Chronic Lymphocytic Leukemia B Cells are Consistent With the Canonical Somatic Hypermutation Process", Blood, 103(9):3490-3495, 2004.			
Examiner Signature	/Cynthia Wilder/			Date Considered	04/10/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no response is required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/591,442
(use as many sheets as necessary)		Filing Date	September 01, 2006
		First Named Inventor	Dena LESHKOWITZ
		Group /Art Unit	1653
		Examiner Name	Not Yet Assigned
Sheet	Of	Attorney Docket Number	32488
	4		
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/CW/	23	Mockridge et al. "Common Patterns of B Cell Perturbation and Expanded V4-34 Immunoglobulin Gene Usage in Autoimmunity and Infection", Autoimmunity, 37(1): 9-15, 2004. Abstract.	
	24	Ogle et al. "Direct Measurement of Lymphocyte Receptor Diversity", Nucleic Acids Research, 31(22):1-6, 2003.	
	25	Ohlin et al. "The Human Antibody Repertoire to Infectious Agents: Implications for Disease Pathogenesis", Molecular Immunology, 40:1-11, 2003.	
	26	Pascual et al. "Heavy Chain Variable Region Gene Utilization in Human Antibodies", International Reviews in Immunology, 5(3-4): 231-238, 1990. Abstract.	
	27	Preparata et al. "Sequencing-by-Hybridization at the Information - Theory Bound: An Optimal Algorithm", Journal of Computational Biology, 7(3/4):621-630, 2000.	
	28	Quackenbush "Microarray Data Normalization and Transformation", Nature Genetics Supplement, 32:496-501, 2002.	
	29	Quintana et al. "Functional Immunomics: Microarray Analysis of IgG Autoantibody Repertoires Predicts the Future Response of Mice to Induced Diabetes", Proc. Natl. Acad. Sci. USA, P. 1-7, 2004.	
	30	Risitano et al. "In-Vivo Dominant Immune Responses in Aplastic Anaemia: Molecular Tracking of Putatively Pathogenetic T-Cell Clones by TCR Beta-CDR3 Sequencing", http://www.thelancet.com , 364:355-364, 2004.	
	31	Ritgen et al. "Unmutated Immunoglobulin Variable Heavy-chain Gene Status Remains an Adverse Prognostic Factor After Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukemia", Blood, 101(5): 2049-2053, 2003.	
	32	Sade et al. "The Effect of Specific Immunotherapy on T-Cell Receptor Repertoire in Patients With Allergy to House-Dust Mite", Allergy, 58:430-434, 2003.	
	33	Shendure et al. "Advanced Sequencing Technologies: Methods and Goals", Nature Reviews, 5:335-344, 2004.	
	34	Shi "Enabling Large-Scale Pharmacogenetic Studies by High-Throughput Mutation Detection and Genotyping Technologies", Clinical Chemistry, 47(2):164-172, 2001.	
	35	Sims et al. "Somatic Hypermutation and Selection of B Cells in Thymic Germinal Centers Responding to Acetylcholine Receptor in Myasthenia Gravis", Journal of Immunology, 167:1935-1944, 2001.	
	36	Tobin et al. "Subsets With Restricted Immunoglobulin Gene Rearrangement Features Indicate A Role for Antigen Selection in the Development of Chronic Lymphocytic Leukemia", Blood, 104(9):2879-2885, 2004.	
	37	Tobin et al. "V(H)3-21 Gene Usage in Chronic Lymphocytic Leukemia -- Characterization of A New Subgroup With Distinct Molecular Features and Poor Survival", Leukemia and Lymphoma, 45(2): 221-228, 2004. Abstract.	
Examiner Signature	/Cynthia Wilder/		Date Considered 04/10/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard St.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



Substitute for form 1449A/PTO

(use as many sheets as necessary)

Complete if Known

Application Number	10/591,442
Filing Date	September 01, 2006
First Named Inventor	Dena LESHKOWITZ
Group Art Unit	1653
Examiner Name	Not Yet Assigned

Attorney Docket Number	32488
------------------------	-------

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner
InitialsCite
No. 1

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

 T^2

/CW/

38

Van Dam et al. "Gene Expression Analysis with Universal n-mer Arrays", Cold Spring Harbor Laboratory Press. *Genome Research*, 12: 145-152, 2002.

/CW/

39

Van Dongen et al. "Design and Standardization of PCR Primers and Protocols for Detection of Clonal Immunoglobulin and T-Cell Receptor Gene Recombinations in Suspect Lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936". *Leukemia*. 17:2257-2317, 2003.

Examiner
Signature

/Cynthia Wilder/

Date
Considered

04/10/2008

² EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ³ Applicant's unique citation designation number (optional). ² See Kinds Codes of (USPTO Patent) Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3)

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁴ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be directed to Washington Headquarters Office of Management and Trademark Office, Paperwork Project Group, Washington, DC 20540. Send comments to Washington, DC 20540. VA 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450